needed effects
cyclophosphamide
active ingredient
neosar
unwanted side effects
medical attention
following side effects
taking cyclophosphamide
check
doctor
cyclophosphamide side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
hematologic side effects
myelosuppression
myelosuppression
leukopenia
common dose-limiting side effect
cyclophosphamide
active ingredient
neosar
anemia
aplastic anemia
case of cyclophosphamide-induced methemoglobinemia
induction therapy
nadir for leukopenia
thrombocytopenia
anemia
days
recovery
days
leukopenia
cyclophosphamide
patient
risk of infection
cyclophosphamide
platelet-sparing agent
significant depression of the platelets
dose of the drug
mg/kg
administered cyclophosphamide
cumulative effect on the bone marrow reserve
chronic oral therapy
complete blood count
cbc
including platelets
weeks
dosage adjustments
serious complication from cyclophosphamide-induced myelosuppression
life-threatening opportunistic infections
sepsis
cyclophosphamide
alkylating agents
relative sparing effect on hematopoietic stem cells
platelets
increased incidence of thromboembolic events
women
receiving cyclophosphamide
methotrexate
fluorouracil as treatment for breast cancer
gastrointestinal side effects
severe emesis
majority of patients
standard
mg/m
> mg/m
cyclophosphamide
active ingredient
neosar
severe nausea
vomiting
patients
cyclophosphamide
anorexia
abdominal discomfort
pain
diarrhea
rare reports of hemorrhagic colitis
oral mucosal ulceration
jaundice
therapy
severity of the emesis
dose of cyclophosphamide
addition of other chemotherapeutic agents
cyclophosphamide-induced nausea
vomiting
days
following chemotherapy
selection of appropriate antiemetic agents
total dose of cyclophosphamide
studies
serotonin-receptor antagonist
ondansetron
granisetron
dexamethasone
optimal emetic control for patients
high-dose cyclophosphamide
> mg/m
cyclophosphamide-containing regimens
significant delayed nausea
vomiting
regimens
prevention
delayed nausea
vomiting
oral metoclopramide
oral ondansetron
dexamethasone
nausea
vomiting
administration
result of direct stimulation of the chemoreceptor trigger zone
dermatologic side effects
alopecia
patients
cyclophosphamide
active ingredient
neosar
skin
nail pigmentation changes
stevens-johnson syndrome
toxic epidermal necrolysis
hair loss
weeks after a single dose
months
hair
different texture
different color
hair regrowth
cyclophosphamide
successive treatments of cyclophosphamide
scalp
cyclophosphamide-induced hair follicle damage
extremity
pubic hair
long-term therapy
definitive causal relationship between stevens-johnson syndrome
toxic epidermal necrolysis
cyclophosphamide
genitourinary side effects
hemorrhagic cystitis
incidence
mortality from uncontrolled hemorrhage
nonhemorrhagic cystitis
bladder fibrosis
hemorrhagic urethritis
irritative voiding
urinary frequency
dysuria
urgency
incontinence
nocturia
renal tubular necrosis
hemorrhagic cystitis
acrolein
product
breakdown of aldophosphamide
phosphoramide mustard
condition
aggressive hydration
liters/day
frequent urinary voiding
use of mesna
thiosulfate
offending
offending metabolic agent
acrolein
cyclophosphamide
higher doses of cyclophosphamide
risk of hemorrhagic cystitis
most circumstances
hemorrhagic cystitis
contraindication
further cyclophosphamide treatment
high-dose therapy
daily urinalysis
urine dipsticks
checking for blood
diagnosis of cyclophosphamide-induced hemorrhagic cystitis
history of gross hematuria
laboratory findings of microscopic hematuria
platelet counts of greater
mm
lack of significant bacterial growth urine culture
risk factors for the development of lung injury after cyclophosphamide
active ingredient
neosar
dosage
age of the patient
disease condition
duration of treatment
predisposing factors
combination of drugs
radiation therapy
oxygen therapy
cyclophosphamide-induced pulmonary toxicity
respiratory side effects
interstitial pulmonary fibrosis
pneumonitis
patients
receiving high doses of cyclophosphamide over a prolonged period
signs
symptoms of lung damage
dyspnea
cough fever
pulmonary edema
abnormal lung sounds
interstitial lung disease
pneumocystis carinii pneumonia
following combination therapy with cyclophosphamide
prednisone
case of fatal pulmonary toxicity after a single dose of cyclophosphamide
cyclophosphamide
pulmonary function
survival benefit in patients with scleroderma
alveolitis
high-dose regimen
splitting
daily dose of cyclophosphamide
active ingredient
neosar
infusions
risk of cardiotoxicity
residual cardiac abnormalities
patients with apparent cardiac toxicity
high doses of cyclophosphamide
limited data
patients for bone marrow transplantation
use of twice-daily regimens
risk of cyclophosphamide-induced systolic dysfunction
cardiovascular
side effects
acute cardiac toxicity
cyclophosphamide doses
g/m
g/m
conjunction with other antineoplastic agents
few cases
congestive heart failure after high dose cyclophosphamide therapy
endocrine side effects
interference with oogenesis
spermatogenesis
cyclophosphamide-induced amenorrhea
decreased estrogen
gonadotropin in women
azoospermia
normal testosterone
gonadotropin in men
cyclophosphamide
active ingredient
neosar
sterility in both sexes
dose
duration of treatment
pretreatment state of gonadal function
syndrome of inappropriate antidiuretic hormone
siadh
hyponatremia
doses
mg/kg
cyclophosphamide-induced sterility
patients
male sexual libido
cyclophosphamide
ovarian fibrosis in women
testicular atrophy in men
prolonged use of this drug
men
women with cyclophosphamide-induced sterility
sperm production
menses
depending
ages at the time of chemotherapy
many affected men
fathered normal children
siadh
cyclophosphamide
increased secretion of antidiuretic hormone
adh
direct effect of cyclophosphamide on the renal tubules
leading
excess water retention
isotonic hydration
short-lived problem
hypersensitivity side effects
rare cases of cutaneous vasculitis
delayed-type reactions
anaphylaxis
death
secondary neoplasias
cyclophosphamide
active ingredient
neosar
monotherapy
drug
other antineoplastic drugs
patients with hemorrhagic cystitis during therapy
patients
underlying
lymphoproliferative malignancies
disorders
greatest risk
cases
new neoplasms
been observed several years after exposure
cyclophosphamide
controlled longitudinal cohort study of patients with severe rheumatoid arthritis
relative risk of malignancy in patients
cyclophosphamide
risk
dose
oncologic side effects
secondary neoplasms
observed secondary malignancies
leukemia
tumors
urinary bladder
nervous system
side effects
ototoxicity
peripheral neuropathy
cyclophosphamide
active ingredient
neosar
other antineoplastic agents
including cisplatin
carboplatin
drugs
ototoxicity
other side effects
asthenia
dizziness
depression
headache
musculoskeletal side effects
musculoskeletal pains
rheumatic syndromes
patients
received regimens
cyclophosphamide
active ingredient
neosar
myalgias
arthralgias
months after completion of adjuvant chemotherapy for breast cancer
side effects of neosar
fda
healthcare professional for medical advice
cough or hoarseness
fever or chills
side pain
missing menstrual periods
difficult urination
blood in the urine
dizziness
confusion
agitation
fast heartbeat
joint pain
shortness of breath
swelling of the feet
lower legs
unusual tiredness
weakness
black, tarry stools
red spots on the skin
unusual bleeding
bruising
frequent urination
redness
swelling
pain at the injection site
sores in the mouth
lips
sudden shortness of breath
unusual thirst
yellow eyes
skin
darkening of the skin
fingernails
loss of appetite
nausea or vomiting
diarrhea
flushing
redness of the face
headache
increased sweating
skin rash
hives
itching
stomach pain
swollen lips